ArticleFrontiers in oncology2022
Novel Diagnostic and Prognostic Tools for Lung Cancer Cachexia: Based on Nutritional and Inflammatory Status.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- The prognostic value of preoperative Naples prognostic score for overall survival and progression-free survival in colorectal cancer.BMC cancer · 2026Article
- The diagnostic value of prognostic nutritional ındex and controlling nutritional status score in differentiating retinal vein occlusion.International ophthalmology · 2026Article
- Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.Journal of cachexia, sarcopenia and muscle · 2025Article
- Nutritional risk, functional decline, and symptom burden in lung cancer: a study based on PG-SGA scores and biochemical data.Frontiers in nutrition · 2025Article
- Swimming upregulates APOL3 through regulating macrophage polarization to inhibit glycolysis and the development of melanoma.3 Biotech · 2024Article
- Incidence of myelosuppression in AML is higher compared with that in ALL.Molecular and clinical oncology · 2024Article
- Serum nutritional predictive biomarkers and risk assessment for anastomotic leakage after laparoscopic surgery in rectal cancer patients.World journal of gastrointestinal surgery · 2024Article
- GastricAITool: A Clinical Decision Support Tool for the Diagnosis and Prognosis of Gastric Cancer.Biomedicines · 2024Article
- Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.Journal of cancer research and clinical oncology · 2024Article
- The dynamics of food for special medical purposes (FSMPs) utilization in cancer care: from doctor recommendations to online pharmacy procurement.Frontiers in pharmacology · 2024Article
- Role of growth differentiation factor 15 in cancer cachexia (Review).Oncology letters · 2023Review
- Relationship between Composite Dietary Antioxidant Index and Aging.Healthcare (Basel, Switzerland) · 2023Article
- Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities.Journal of the National Cancer Institute. Monographs · 2023Article
- The prognostic effect of sixteen malnutrition/inflammation-based indicators on the overall survival of chemotherapy patients.Frontiers in immunology · 2023Article
- Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study.Technology in cancer research & treatmentObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cachexia is one of the most common complications affecting lung cancer patients that seriously affects their quality-of-life and survival time. This study aimed to analyze the predictors and prognostic factors of lung cancer cachexia as well as to develop a convenient and accurate clinical prediction tool for oncologists. Methods: In this multicenter cohort study, 4022 patients with lung cancer were retrospectively analyzed. The patients were randomly categorized into training and verification sets (7:3 ratio). Univariate and multivariate logistic regression analyses were performed to determine the risk factors of cachexia in patients with lung cancer. Cox regression analysis was applied to determine independent prognostic factors in the patients with lung cancer cachexia. Meanwhile, two nomograms were established and evaluated by time-dependent receiver operating characteristic curve, calibration curve, and decision curve analysis (DCA). Results: Stage, serum albumin, ALI, anemia, and surgery were independent risk factors for cachexia in patients with lung cancer. Patients with lung cancer cachexia have a shorter survival time. Sex, stage, serum albumin, ALI, KPS score, and surgery served as independent prognostic factors for patients with lung cancer cachexia. The area under the curves (AUCs) of diagnostic nomogram in the training and validation sets were 0.702 and 0.688, respectively, the AUCs of prognostic nomogram in the training set for 1-, 3-, and 5-year were 0.70, 0.72, and 0.75, respectively, while in the validation set the AUCs were 0.71, 0.75, and 0.79, respectively. The calibration curves and DCA of the two nomograms were consistent and the clinical benefit rate was high. Conclusion: Cachexia brings an additional economic burden and worsens the prognosis of lung cancer patients. The two nomograms can accurately screen and predict the probability of occurrence of cachexia in lung cancer and the prognosis of patients with lung cancer cachexia, and guide clinical work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.